International experience of using olaparib for metastatic castration-resistant prostate cancer: literature review

被引：0
|
作者：
Matveev, V. B. [1 ]
Khalmurzaev, O. A. [1 ]
Evsyukova, O., I [1 ]
机构：
[1] Minist Hlth Russia, NN Blokhin Natl Med Res Ctr Oncol, 24 Kashirskoe Shosse, Moscow 115478, Russia
来源：
ONKOUROLOGIYA | 2020年 / 16卷 / 04期
关键词：
prostate cancer; HRR mutations; BRCA; olaparib; DNA-REPAIR;
D O I：
10.17650/1726-9776-2020-16-4-197-206
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The following review presents a problem of metastatic castration-resistant prostate cancer and its association with germline or somatic mutations in homologous recombination repair (HRR). In 2020, olaparib was approved in the Russian Federation as a monotherapy for metastatic castration-resistant prostate cancer with germline or somatic mutations of genes involved in DNA repair by homologous recombination, after progression on therapy with new hormonal drugs. We describe a review of the main olaparib clinical trials assessing its efficacy, safety and tolerance in metastatic castration-resistant prostate cancer patients.
引用
收藏
页码：197 / 206
页数：10
相关论文
共 50 条
  • [41] Enzalutamide: A Review of Its Use in Metastatic, Castration-Resistant Prostate Cancer
    Sanford, Mark
    DRUGS, 2013, 73 (15) : 1723 - 1732
  • [42] Systemic Therapies for Metastatic Castration-Resistant Prostate Cancer: An Updated Review
    Hatano, Koji
    Nonomura, Norio
    WORLD JOURNAL OF MENS HEALTH, 2023, 41 (04): : 769 - 784
  • [43] Enzalutamide: A Review of Its Use in Metastatic, Castration-Resistant Prostate Cancer
    Mark Sanford
    Drugs, 2013, 73 : 1723 - 1732
  • [44] Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
    Lesley J. Scott
    Targeted Oncology, 2020, 15 : 791 - 799
  • [45] Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science
    N Nussbaum
    D J George
    A P Abernethy
    C M Dolan
    N Oestreicher
    S Flanders
    T B Dorff
    Prostate Cancer and Prostatic Diseases, 2016, 19 : 111 - 121
  • [46] Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science
    Nussbaum, N.
    George, D. J.
    Abernethy, A. P.
    Dolan, C. M.
    Oestreicher, N.
    Flanders, S.
    Dorff, T. B.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2016, 19 (02) : 111 - 121
  • [47] Bipolar androgen therapy (BAT) plus olaparib in men with metastatic castration-resistant prostate cancer (mCRPC)
    Schweizer, M.
    Gulati, R.
    Yezefski, T.
    Cheng, H.
    Sievers, C.
    Dumpit, R.
    Alexander, K.
    McDonald, N.
    Lai, M.
    Nega, K.
    Hammond, J.
    Grivas, P.
    Hsieh, A.
    Montgomery, B.
    Nelson, P.
    Yu, E.
    ANNALS OF ONCOLOGY, 2021, 32 : S639 - S640
  • [48] Abiraterone in the treatment of metastatic castration-resistant prostate cancer
    Mostaghel, Elahe A.
    CANCER MANAGEMENT AND RESEARCH, 2014, 6 : 39 - 51
  • [49] Immune Biomarkers in Metastatic Castration-resistant Prostate Cancer
    de la Maza, Maria Dolores Fenor
    Chandran, Khobe
    Rekowski, Jan
    Shui, Irene M.
    Gurel, Bora
    Cross, Emily
    Carreira, Suzanne
    Yuan, Wei
    Westaby, Daniel
    Miranda, Susana
    Ferreira, Ana
    Seed, George
    Crespo, Mateus
    Figueiredo, Ines
    Bertan, Claudia
    Gil, Veronica
    Riisnaes, Ruth
    Sharp, Adam
    Rodrigues, Daniel Nava
    Rescigno, Pasquale
    Tunariu, Nina
    Liu, Xiao Qiao
    Cristescu, Razvan
    Schloss, Charles
    Yap, Christina
    Bono, Johann S. de
    EUROPEAN UROLOGY ONCOLOGY, 2022, 5 (06): : 659 - 667
  • [50] Trial design for metastatic castration-resistant prostate cancer
    Sonpavde, Guru
    Fleming, Mark T.
    Hutson, Thomas E.
    Galsky, Matthew D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (21) : 3647 - 3648
12345